Ratios Uncovered: Breaking Down Oncology Institute Inc (TOI)’s Trailing Twelve Months Metrics

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

The price of Oncology Institute Inc (NASDAQ: TOI) closed at $2.47 in the last session, down -6.79% from day before closing price of $2.65. In other words, the price has decreased by -$6.79 from its previous closing price. On the day, 1.48 million shares were traded.

Ratios:

We take a closer look at TOI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.59 and its Current Ratio is at 1.79. In the meantime, Its Debt-to-Equity ratio is 20.18 whereas as Long-Term Debt/Eq ratio is at 18.83.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 15, 2025, initiated with a Buy rating and assigned the stock a target price of $7.

On September 14, 2022, Guggenheim started tracking the stock assigning a Buy rating and target price of $7.Guggenheim initiated its Buy rating on September 14, 2022, with a $7 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 05 ’25 when M33 Growth I L.P. sold 673,676 shares for $3.05 per share. The transaction valued at 2,054,712 led to the insider holds 13,950,557 shares of the business.

M33 Growth I L.P. sold 76,324 shares of TOI for $232,788 on Jun 05 ’25. The Director now owns 1,272,724 shares after completing the transaction at $3.05 per share. On Jun 03 ’25, another insider, Hively Brad, who serves as the Director of the company, sold 1,976,137 shares for $2.87 each. As a result, the insider received 5,672,106 and left with 603,501 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.56 while its Price-to-Book (P/B) ratio in mrq is 43.33.

Stock Price History:

Over the past 52 weeks, TOI has reached a high of $3.50, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is -4.58%, while the 200-Day Moving Average is calculated to be 143.66%.

Shares Statistics:

A total of 88.93M shares are outstanding, with a floating share count of 40.96M. Insiders hold about 55.44% of the company’s shares, while institutions hold 14.73% stake in the company.

Earnings Estimates

The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.

Revenue Estimates

According to 1 analysts, the current quarter’s revenue is expected to be $112.56M. It ranges from a high estimate of $112.56M to a low estimate of $112.56M. As of the current estimate, Oncology Institute Inc’s year-ago sales were $98.58MFor the next quarter, 1 analysts are estimating revenue of $119.49M. There is a high estimate of $119.49M for the next quarter, whereas the lowest estimate is $119.49M.

Based on 1 analysts’ estimates, the company’s revenue will be $536.33M in the next fiscal year. The high estimate is $536.33M and the low estimate is $536.33M.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.